Obesity
Conditions
Brief summary
The primary objective is to evaluate the overarching hypothesis that obese and black individuals have relatively lower circulating natriuretic peptide levels compared with lean and white individuals. Conventional clinical assays for measurement of circulating natriuretic peptides display substantial overlap, precluding determination of the basis of the relative natriuretic peptide deficiency previously observed in these groups. We will study lean or obese, black or white, healthy adult subjects with intravenous (IV) saline infusion as a stimulus for natriuretic peptide production and release. We will measure circulating levels of natriuretic peptide isoforms using mass spectrometry that allows the specific identification of proBNP 1-108 and its cleavage product BNP 1-32.
Interventions
Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
Sponsors
Vanderbilt University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 18 and 65 years; * BMI between 18 and 25 (lean) or 30 and 40 kg/m2 (obese); * self-reported race of either black or white; * otherwise healthy with no chronic comorbidities.
Exclusion criteria
* History of diabetes mellitus * Currently pregnant * History of cardiac disorder including heart failure, cardiomyopathy, myocardial infarction, coronary revascularization, abnormal stress test, uncontrolled arrhythmia or arrhythmia requiring treatment, congenital heart disease, pericardial disease. * History of hypertension defined as taking anti-hypertensive medications or untreated hypertension with systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at most recent clinical visit or screening visit. * Obstructive lung disease * History of chronic kidney disease * History of liver disease or cirrhosis * Uncontrolled thyroid dysfunction * History of solid organ transplant * History of malignancy other than basal or squamous cell skin cancer * Inability to lie flat for 6 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in circulating levels of proBNP 1-108 from baseline to 6 hours | Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total | proBNP 1-108 is a protein made by the heart. The change in circulating levels will be measured in response to saline infusion |
| Change in circulating levels of proBNP 1-32 from baseline to 6 hours | Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total | BNP 1-32 is a hormone made by the heart. The change in circulating levels will be measured in response to saline infusion |
Countries
United States
Outcome results
None listed